Is DWTX or ZNTL more profitable?

Zentalis Pharmaceuticals' return on equity of -70.18% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dogwood Therapeutics N/A -75.55% -40.28% Zentalis Pharmaceuticals N/A -70.18% -51.46%

Does the media favor DWTX or ZNTL?

In the previous week, Zentalis Pharmaceuticals had 2 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 4 mentions for Zentalis Pharmaceuticals and 2 mentions for Dogwood Therapeutics. Dogwood Therapeutics' average media sentiment score of 0.25 beat Zentalis Pharmaceuticals' score of 0.17 indicating that Dogwood Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dogwood Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zentalis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, DWTX or CRDL?

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dogwood Therapeutics N/A N/A -$34.26M -$8.95 N/A Cardiol Therapeutics N/A N/A -$24.20M -$0.25 N/A

Is DWTX or CRDL more profitable?

Dogwood Therapeutics' return on equity of -75.55% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dogwood Therapeutics N/A -75.55% -40.28% Cardiol Therapeutics N/A -180.44% -140.28%

Does the media refer more to DWTX or CRDL?

In the previous week, Cardiol Therapeutics had 2 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 4 mentions for Cardiol Therapeutics and 2 mentions for Dogwood Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.62 beat Dogwood Therapeutics' score of 0.25 indicating that Cardiol Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dogwood Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardiol Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SIGA or DWTX?

Dogwood Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 650.00%. Given Dogwood Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dogwood Therapeutics is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dogwood Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer DWTX or DERM?

In the previous week, Dogwood Therapeutics and Dogwood Therapeutics both had 2 articles in the media. Journey Medical's average media sentiment score of 1.40 beat Dogwood Therapeutics' score of 0.25 indicating that Journey Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dogwood Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Journey Medical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, DWTX or ANTX?

Anthem is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dogwood Therapeutics N/A N/A -$34.26M -$8.95 N/A Anthem N/A N/A -$35.17M -$1.07 N/A

Is DWTX or ANTX more profitable?

Anthem's return on equity of -53.52% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dogwood Therapeutics N/A -75.55% -40.28% Anthem N/A -53.52% -48.63%

Does the media refer more to DWTX or ANTX?

In the previous week, Dogwood Therapeutics had 1 more articles in the media than Anthem. MarketBeat recorded 2 mentions for Dogwood Therapeutics and 1 mentions for Anthem. Dogwood Therapeutics' average media sentiment score of 0.25 beat Anthem's score of 0.00 indicating that Dogwood Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dogwood Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anthem 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Dogwood Therapeutics (DWTX) Competitors

$1.60 -0.09 (-5.33%)

As of 04:00 PM Eastern

Compare

DWTX vs. ZNTL, CRDL, SIGA, DERM, and ANTX

Should you buy Dogwood Therapeutics stock or one of its competitors? Dogwood Therapeutics's main competitors and comparable companies include Zentalis Pharmaceuticals (ZNTL), Cardiol Therapeutics (CRDL), Siga Technologies (SIGA), Journey Medical (DERM), and Anthem (ANTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Dogwood Therapeutics compare to Zentalis Pharmaceuticals?

Dogwood Therapeutics (NASDAQ:DWTX) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

Dogwood Therapeutics has a beta of 1.81, indicating that its stock price is 81% more volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.85, indicating that its stock price is 85% more volatile than the broader market.

In the previous week, Zentalis Pharmaceuticals had 2 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 4 mentions for Zentalis Pharmaceuticals and 2 mentions for Dogwood Therapeutics. Dogwood Therapeutics' average media sentiment score of 0.25 beat Zentalis Pharmaceuticals' score of 0.17 indicating that Dogwood Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dogwood Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zentalis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dogwood Therapeutics has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$8.95	N/A
Zentalis Pharmaceuticals	$67.43M	3.22	-$137.06M	-$1.95	N/A

Zentalis Pharmaceuticals' return on equity of -70.18% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-75.55%	-40.28%
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%

Dogwood Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 650.00%. Zentalis Pharmaceuticals has a consensus target price of $6.75, indicating a potential upside of 122.77%. Given Dogwood Therapeutics' higher probable upside, analysts plainly believe Dogwood Therapeutics is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40

9.1% of Dogwood Therapeutics shares are owned by institutional investors. 0.3% of Dogwood Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Zentalis Pharmaceuticals beats Dogwood Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Cardiol Therapeutics?

Dogwood Therapeutics (NASDAQ:DWTX) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

Dogwood Therapeutics has a beta of 1.81, meaning that its share price is 81% more volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

In the previous week, Cardiol Therapeutics had 2 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 4 mentions for Cardiol Therapeutics and 2 mentions for Dogwood Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.62 beat Dogwood Therapeutics' score of 0.25 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dogwood Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardiol Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$8.95	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A

Dogwood Therapeutics' return on equity of -75.55% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-75.55%	-40.28%
Cardiol Therapeutics	N/A	-180.44%	-140.28%

Dogwood Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 650.00%. Cardiol Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 437.63%. Given Dogwood Therapeutics' higher possible upside, research analysts plainly believe Dogwood Therapeutics is more favorable than Cardiol Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

9.1% of Dogwood Therapeutics shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 0.3% of Dogwood Therapeutics shares are owned by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Cardiol Therapeutics beats Dogwood Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

55.4% of Siga Technologies shares are owned by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are owned by institutional investors. 2.7% of Siga Technologies shares are owned by insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Dogwood Therapeutics had 2 more articles in the media than Siga Technologies. MarketBeat recorded 2 mentions for Dogwood Therapeutics and 0 mentions for Siga Technologies. Siga Technologies' average media sentiment score of 0.92 beat Dogwood Therapeutics' score of 0.25 indicating that Siga Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Siga Technologies	Positive
Dogwood Therapeutics	Neutral

Siga Technologies has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.81, indicating that its stock price is 81% more volatile than the broader market.

Dogwood Therapeutics has a net margin of 0.00% compared to Siga Technologies' net margin of -5.19%. Siga Technologies' return on equity of -1.55% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	-5.19%	-1.55%	-1.32%
Dogwood Therapeutics	N/A	-75.55%	-40.28%

Dogwood Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 650.00%. Given Dogwood Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dogwood Therapeutics is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Siga Technologies has higher revenue and earnings than Dogwood Therapeutics. Siga Technologies is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57M	2.40	$23.28M	-$0.05	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$8.95	N/A

Summary

Siga Technologies beats Dogwood Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Journey Medical?

Dogwood Therapeutics (NASDAQ:DWTX) and Journey Medical (NASDAQ:DERM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

9.1% of Dogwood Therapeutics shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 0.3% of Dogwood Therapeutics shares are held by insiders. Comparatively, 14.5% of Journey Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Dogwood Therapeutics and Dogwood Therapeutics both had 2 articles in the media. Journey Medical's average media sentiment score of 1.40 beat Dogwood Therapeutics' score of 0.25 indicating that Journey Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dogwood Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Journey Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dogwood Therapeutics has a beta of 1.81, meaning that its share price is 81% more volatile than the broader market. Comparatively, Journey Medical has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

Dogwood Therapeutics has a net margin of 0.00% compared to Journey Medical's net margin of -8.95%. Journey Medical's return on equity of -20.23% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-75.55%	-40.28%
Journey Medical	-8.95%	-20.23%	-6.60%

Journey Medical has higher revenue and earnings than Dogwood Therapeutics. Journey Medical is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$8.95	N/A
Journey Medical	$61.86M	3.19	-$11.43M	-$0.22	N/A

Dogwood Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 650.00%. Journey Medical has a consensus price target of $14.00, suggesting a potential upside of 100.29%. Given Dogwood Therapeutics' higher possible upside, equities research analysts clearly believe Dogwood Therapeutics is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Journey Medical beats Dogwood Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Anthem?

Dogwood Therapeutics (NASDAQ:DWTX) and Anthem (NASDAQ:ANTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

Dogwood Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 650.00%. Anthem has a consensus price target of $9.00, indicating a potential upside of 81.45%. Given Dogwood Therapeutics' higher possible upside, equities analysts plainly believe Dogwood Therapeutics is more favorable than Anthem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Dogwood Therapeutics has a beta of 1.81, suggesting that its share price is 81% more volatile than the broader market. Comparatively, Anthem has a beta of -0.99, suggesting that its share price is 199% less volatile than the broader market.

Anthem's return on equity of -53.52% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-75.55%	-40.28%
Anthem	N/A	-53.52%	-48.63%

9.1% of Dogwood Therapeutics shares are owned by institutional investors. Comparatively, 90.5% of Anthem shares are owned by institutional investors. 0.3% of Dogwood Therapeutics shares are owned by company insiders. Comparatively, 22.6% of Anthem shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Anthem is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$8.95	N/A
Anthem	N/A	N/A	-$35.17M	-$1.07	N/A

In the previous week, Dogwood Therapeutics had 1 more articles in the media than Anthem. MarketBeat recorded 2 mentions for Dogwood Therapeutics and 1 mentions for Anthem. Dogwood Therapeutics' average media sentiment score of 0.25 beat Anthem's score of 0.00 indicating that Dogwood Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dogwood Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anthem	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Dogwood Therapeutics and Anthem tied by winning 6 of the 12 factors compared between the two stocks.

Get Dogwood Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DWTX vs. The Competition

Export

Metric	Dogwood Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$57.45M	$12.51B	$7.26B	$13.23B
Dividend Yield	N/A	2.64%	2.53%	12.80%
P/E Ratio	N/A	794.81	275.56	25.79
Price / Sales	N/A	796.68	693.67	102.99
Price / Cash	N/A	15.08	28.04	34.72
Price / Book	0.69	10.57	10.56	6.36
Net Income	-$34.26M	$2.82B	$3.49B	$358.17M
7 Day Performance	-13.28%	-0.36%	-0.23%	0.54%
1 Month Performance	-35.74%	-1.19%	-2.80%	-2.95%
1 Year Performance	-68.06%	4.01%	18.25%	6.08%

Dogwood Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DWTX Dogwood Therapeutics	2.3911 of 5 stars	$1.60 -5.3%	$12.00 +650.0%	-66.3%	$57.45M	N/A	N/A	8
ZNTL Zentalis Pharmaceuticals	3.5548 of 5 stars	$3.14 +0.4%	$6.75 +114.7%	+104.6%	$225.40M	$67.43M	N/A	106
CRDL Cardiol Therapeutics	2.7212 of 5 stars	$1.85 -0.3%	$10.00 +442.0%	+67.4%	$214.35M	N/A	N/A	18
SIGA Siga Technologies	0.7288 of 5 stars	$2.94 -1.4%	N/A	-64.2%	$212.75M	$94.57M	N/A	49	News Coverage
DERM Journey Medical	1.8108 of 5 stars	$7.46 +1.4%	$14.00 +87.7%	+0.1%	$210.52M	$61.86M	N/A	58	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DWTX) was last updated on 9/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dogwood Therapeutics (DWTX) Competitors

DWTX vs. ZNTL, CRDL, SIGA, DERM, and ANTX

How does Dogwood Therapeutics compare to Zentalis Pharmaceuticals?

Summary

How does Dogwood Therapeutics compare to Cardiol Therapeutics?

Summary

How does Dogwood Therapeutics compare to Siga Technologies?

Summary

How does Dogwood Therapeutics compare to Journey Medical?

Summary

How does Dogwood Therapeutics compare to Anthem?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DWTX vs. The Competition

Dogwood Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dogwood Therapeutics (DWTX) Competitors

DWTX vs. ZNTL, CRDL, SIGA, DERM, and ANTX

How does Dogwood Therapeutics compare to Zentalis Pharmaceuticals?

Which has more risk & volatility, DWTX or ZNTL?

Does the media favor DWTX or ZNTL?

Which has better valuation & earnings, DWTX or ZNTL?

Is DWTX or ZNTL more profitable?

Do analysts recommend DWTX or ZNTL?

Do institutionals and insiders believe in DWTX or ZNTL?

Summary

How does Dogwood Therapeutics compare to Cardiol Therapeutics?

Which has more risk & volatility, DWTX or CRDL?

Does the media refer more to DWTX or CRDL?

Which has higher earnings & valuation, DWTX or CRDL?

Is DWTX or CRDL more profitable?

Do analysts prefer DWTX or CRDL?

Do insiders and institutionals hold more shares of DWTX or CRDL?

Summary

How does Dogwood Therapeutics compare to Siga Technologies?

Do institutionals and insiders hold more shares of SIGA or DWTX?

Does the media refer more to SIGA or DWTX?

Which has more volatility & risk, SIGA or DWTX?

Is SIGA or DWTX more profitable?

Do analysts recommend SIGA or DWTX?

Which has stronger earnings & valuation, SIGA or DWTX?

Summary

How does Dogwood Therapeutics compare to Journey Medical?

Do insiders & institutionals hold more shares of DWTX or DERM?

Does the media prefer DWTX or DERM?

Which has more volatility & risk, DWTX or DERM?

Is DWTX or DERM more profitable?

Which has preferable valuation & earnings, DWTX or DERM?

Do analysts rate DWTX or DERM?

Summary

How does Dogwood Therapeutics compare to Anthem?

Do analysts rate DWTX or ANTX?

Which has more risk & volatility, DWTX or ANTX?

Is DWTX or ANTX more profitable?

Do institutionals & insiders believe in DWTX or ANTX?

Which has preferable earnings & valuation, DWTX or ANTX?

Does the media refer more to DWTX or ANTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DWTX vs. The Competition

Dogwood Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools